---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-007032"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:29:03.496521+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Zevra Therapeutics reports FY 2024 net loss of $105.5M; sells PRV for $150M, cash runway into 2029

## Summary
- FY 2024 net revenue $23.6M (record Q4 product revenue $10.2M from MIPLYFFA); net loss ($105.5M) vs ($46.0M) in 2023.
- Entered asset purchase agreement to sell Rare Pediatric Disease PRV for $150M gross; expected net proceeds $148.3M.
- Cash and investments $75.5M at Dec 31, 2024; with PRV sale, cash runway extends into 2029; no going concern disclosure.
- MIPLYFFA commercial launch: 109 total prescription enrollment forms as of Dec 31; EU filing targeted H2 2025.
- OLPRUVA added 4 new patients Q4; DiSCOVER trial (VEDS) enrolled 27 patients; strategic review for KP1077 ongoing.

## SEC filing metadata
- accession: 0001437749-25-007032
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774925007032/0001437749-25-007032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774925007032/zvra20240918_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-007032
- JSON: https://secwatch.observer/filing/0001437749-25-007032.json
- Plain text: https://secwatch.observer/filing/0001437749-25-007032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.